A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab for the Prevention of Recurrence of Nasal Polyps Following Surgical Removal in Patients with Chronic Rhinosinusitis with Nasal Polyps (OXALIS)
Latest Information Update: 19 Jul 2021
At a glance
- Drugs Benralizumab (Primary)
- Indications Nasal polyps; Rhinosinusitis
- Focus Registrational; Therapeutic Use
- Acronyms OXALIS
- Sponsors AstraZeneca AB
- 17 Jul 2021 This trial has been Discontinued in Poland , according to European Clinical Trials Database record.(end date: 2021-03-12 ).
- 18 Jun 2021 This trial has been Discontinued in Hungary, according to European Clinical Trials Database record.
- 16 May 2021 This trial has been completed in Poland, according to European Clinical Trials Database record.